2. Клинические рекомендации амиодарон-индуцированная дисфункция щитовидной железы 2021 г. РАЭ.

3. Bogazzi F., Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010;95:2529–35. Doi: 10.1210/jc.2010-0180.

4. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a13a3b57-bbd3-4ee6-b38f-7b35a87bbc4c&t= (accessed 04.03.2023).

5. Fukuchi H., Nakashima M., Araki R., et al. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. J Clin Pharm Ther. 2009;34:329–36. Doi: 10.1111/j.1365-2710.2008.00987.x.

6. Maqdasy S., et al. Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature. Ann Endocrinol (Paris). 2019;80(1):54–60. Doi: 10.1016/j.ando.2018.05.001.

7. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935–41. Doi: 10.1056/NEJMct065916.

8. Преображенский Д.В., Сидоренко Б.А., Патарая С.А., Киктев В.Г. Амиодарон (Кордарон): антиаритмический препарат с широким диапазоном клинического применения. Русский медицинский журнал. 2008;16(25):1569–666.

9. Ross D.S., Burch H.B., Cooper S., et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421. Doi: 10.1089/thy.2016.0229.

10. Lambert M.J., Burger A.G., Galeazzi R.L., Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 monodeiodination indicative of hyperthyroidism? J Clin Endocrinol Metab. 1982;55:1058–65. Doi: 10.1210/jcem-55-6-1058.

11. Martino E., Bartalena L., Bogazzi F., Braverman L.E.The effects of amiodarone on the thyroid. Endocr Rev. 2001;22:240–54. Doi: 10.1210/edrv.22.2.0427.

12. Heger J.J., Prystowsky E.N., Jackman W.M., et al. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981;305:539–45. Doi: 10.1056/NEJM198109033051002.

13. Trip M.D., Wiersinga W., Plomp Т.A. Incidence, Predictability, and Pathogenesis of Amiodarone-lnduced Thyrotoxicosis and Hypothyroidism. Am J Med. 1991;9:507–11. Doi: 10.1016/0002-9343(91)90187-3.

14. Bogazzi F., Bartalena L., Dell’Unto E., et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf). 2007;67:533–37. Doi: 10.1111/j.1365-2265.2007.02920.x.

15. Yamato M., Wada K., Hayashi T., et al. Association between Serum Amiodarone and NDesethylamiodarone Concentrations and Development of Thyroid Dysfunction. Clin Drug Investig. 2018;38(1):39–48. Doi: 10.1007/s40261-017-0582-4.

16. Tanda M.L., Piantanida E., Lai A., et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008;69:812–18. Doi: 10.1111/j.1365-2265.2008.03268.x.

17. Демидова Т.Ю., Кишкович Ю.С., Ладыгина Д.О.Ведение пациентов с амиодарон-ассоциированной дисфункцией щитовидной железы. Новости Европейской тиреоидологической ассоциации 2018 г. Русский медицинский журнал. 2018;11:101–4.

18. Трошина Е.А. К вопросу о недостатке и избытке йода в организме человека. Клиническая и экспериментальная тиреоидология. 2010;6(4):9–16.

19. Лебедева Е.А., Яблонская Ю.А., Булгакова С.В.Амиодарон-индуцированный тиреотоксикоз. Современный взгляд на проблему. Клиническая и экспериментальная тиреоидология. 2017;13(2):31–8.

20. Платонова Н.М. Современные аспекты диагностики и лечения амиодарон-индуцированного тиреотоксикоза. Поликлиника. 2016;1(2):45–50.

21. Эндокринология: национальное руководство. Под ред. И.И. Дедова, ГА. Мельниченко. М: ГЭОТАР-Медиа. 2019. 1112 с.

22. Klein I., Becker D.V., Levey G.S. Treatment of hyperthyroid disease. Ann Intern Med. 1994;121:281–88. doi: 10.7326/0003-4819-121-4-199408150-00010.

23. Kocher T. Ueber jodbasedow. Arch F Klin Chir. 1910;92:1166.

24. Theodoraki A., Vanderpump M.P.J. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf). 2016;84:172–76. Doi: 10.1111/cen.12988.

25. Eaton S.E., Euinton H.A., Newman C.M., et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role ofcolour-flow Doppler sonography. Clin Endocrinol

26. Bartalena L., Brogioni S., Grasso L., et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 1996;81:2930–33. Doi: 10.1210/jcem.81.8.8768854.

27. Wong R., Cheung W., Stockigt J.R., Topliss D.J.Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Intern Med J. 2003;33:420–26. Doi: 10.1046/j.1445-5994.2003.00463.x.

28. Tomisti L., Rossi G., Bartalena L., et al. The onset time of amiodarone-induced thyrotoxicosis

29. Wendy T., Robyn L. H. Amiodarone-induced thyrotoxicosis: A review. Can J Cardiol. 2009;25(7):421–24. Doi: 10.1016/s0828-282x(09)70512-4.

30. Piga M., Cocco M.C., Serra A., et al. The usefulness of 99mTc-sesta MIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008;159:423–29. Doi: 10.1530/EJE-08-0348.

31. Censi S., Bodanza V., Manso J., et al. Amiodarone-Induced Thyrotoxicosis: Differential Diagnosis Using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR). Clin Nucl Med. 2018;43(9):655–62. Doi: 10.1097/RLU.0000000000002207.

32. URL: https://1xmatch.com/mocaheart-analiziruet-krovotok-v-rezhime-real-nogo-vremeni/ (accessed 04.03.2023).

33. Молашенко Н.В., Свириденко Н.Ю., Платоно-ва Н.М. и др. Особенности тиреотоксикоза и тиреоидной гипертироксинемии при применении кордарона. Клиническая медицина. 2004;82(12):35–39.

34. Bogazzi F., Bartalena L., Tomisti L., et al. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. J Clin Endocrinol Metab. 2011;96:3374–80. Doi: 10.1210/jc.2011-1678.

35. Улупова Е.О., Богданова Г.А., Каронова Т.Л.,Гринева Е.Н. Соотношение свободных тиреоидных гормонов в сыворотке крови больных амиодарон-индуцированным тиреотоксикозом 1-го и 2-го типов. Трансляционная медицина. 2018;5(3):28–35.

36. Tamai H., Nozaki T., Mukuta T., et al. The incidence of thyroid stimulating blocking antibodies during the hypothyroid phase in patients with subacute thyroiditis. J Clin Endocrinol Metab. 1991;73:245–50. Doi: 10.1210/jcem-73-2-245.

37. Safran M., Martino E., Aghini-Lombardi F., et al. Effect of amiodarone on circulating anti-thyroid antibodies. Br Med J. 1988;297:456–57. Doi: 10.1136/bmj.297.6646.456.

38. Bartalena L., Grasso L., Brogioni S., et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 1994;789:423–27. Doi: 10.1210/jcem.78.2.8106631.

39. Мацуева И.А., Далматова А.Б., Андрейченко Т.В.,Гринева Е.Н. Лечение тиреотоксикоза карбонатом лития, случаи из практики. Клиническая и экспериментальная тиреоидология. 2021;17(3):22–6.

40. Campi I., Perego G.B., Ravoli A., et al. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2019;181:519–24. Doi: 10.1530/EJE-19-0515.

41. Cappellani D., Urbani C., Manetti L., et al. Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. Springer. 2020;43(11):1637–43. Doi: 10.1007/s40618-020-01252-2.

42. Han T.S., Williams G.R., Vanderpump M.P. Benzofuran derivatives and the thyroid. Clin. Endocrinol (Oxf). 2009;70:2–13. Doi: 10.1111/j.1365-2265.2008.03350.x.

43. Erdogan M.F., Guleс S., Tutar E., et al. A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. Thyroid. 2003;13:205–9. Doi: 10.1089/105072503321319521.

44. Eskes A., Endert E., Fliers E., et al. Treatment of Amiodarone-Induced Thyrotoxicosis Type 2: A Randomized Clinical Trial. Clinical Endocrinology & Metabolism. 2012;97(2):499–506. Doi: 10.1210/jc. 2011–2390.

45. Faizel O., Jayne A. F., Michael C. S., Michael D. G. Successful Treatment of Amiodarone-Induced Thyrotoxicosis Circulation. 2002;105:1275–77. Doi: 10.1161/circ.105.11.1275.

46. Cappellani D., Papini P., Pingitore A., et al. Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxocosis. J Clin Endocrinol Metab. 2020;105(1):242–51. Doi: 10.1210/clinem/dgz041.

47. Клинические рекомендации по острым и хроническим тиреоидитам (исключая аутоиммунный тиреоидит) 2020 г. РАЭ.